Watching what we eat and how much we eat may be an effective tool to manage the toxicity of chemotherapy drugs says this month's online article in the New England Journal of Medicine.
Thursday, June 28, 2012
Wednesday, June 27, 2012
Last June, a Romanian start-up Cronian Labs released an iPhone app Skin Scan which claimed that it can help with early diagnosis (or warning signs) of melanoma. The availability of Skin Scan at Apple iTunes Store was widely covered in the media (eg, read here and here). And, it was also the first time I put medical apps on my radar screen.
There are now hundreds of medical apps, and it is not unsurprising to find oncologists and cancer researchers using a variety of these as reference tools, calculators and diagnostic aids. Here is a short list:
Thursday, June 21, 2012
In the run up to the Targeting the Tumor Microenvironment meeting, taking place in Boston, this October, there are some great resources available to you to download free of charge from the website resources page.
"Targeting the Tumor Microenvironment" meeting will take place in Boston in October and will be looking at how to achieve tumor delivery, tackle drug resistance and improve clinical efficacy.
Thursday, June 7, 2012
Tuesday, June 5, 2012
Smoking causes 5-6 million avoidable deaths annually worldwide. One in 5 men and 1 in 20 women who die after age 30 die of smoking-related causes.
These distressing numbers should be enough to galvanize the California voters who will decide to accept or reject the California Cancer Research Act, commonly called Proposition 29 (or Prop 29). If Prop 29 passes, the money raised through new taxes on cigarettes will support research into smoking-related diseases.
Monday, June 4, 2012
Sunday, June 3, 2012
Phase 3 date on abiraterone trial in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (mCRPC) was profiled in the ASCO daily news. These results have the potential of changing the standard of care in mCRPC.
Friday, June 1, 2012
Two months ago, Trastuzumab Emtansine (T-DM1) metastatic breast cancer trial (called EMILIA trial) reached a major milestone when patients treated with T-DM1 had longer cancer-free periods, also called progression-free survival or PFS, compared to those patients who were on a combination chemotherapy consisting of lapatinib (Tykerb) and capecitabine (Xeloda). (read here). Today, NBC Nightly News gave a human face to this trial.
In a new series on this blog called "Choosing Cancer Charity," I have chosen to present CureSearch National Childhood Cancer Foundation, also called CureSearch for Children's Cancer to the readers this month. There are several reasons that motivates me to pitch this charity for your dollars, and donations of time, expertise and support.